Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes:: a Go-DARTS study
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes:: a Go-DARTS study
复制标题
DOI：
10.1097/fpc.0b013e3282f60aad
复制
发表时间：
2008-04-01
影响因子：
2.6
通讯作者：
Donnan, Peter T.
中科院分区：
文献类型：
--
作者：
Donnelly, Louise A.;Palmer, Colin N. A.;Donnan, Peter T.
背景 载脂蛋白 E (APOE) 基因型与血浆脂质水平的变化和对他汀类药物的反应有关，尽管 APOE 对他汀类药物反应的影响仍然存在争议，特别是在糖尿病患者中。我们试图在一个大型糖尿病患者队列中评估 APOE 基因型与他汀类药物降低低密度脂蛋白胆固醇 (LDLc) 反应之间的关系。 方法和结果 从苏格兰泰赛德糖尿病遗传学审计和研究数据库中鉴定出 1990 年至 2006 年间开始服用他汀类药物的总共 1383 名患者。他汀类药物的反应取决于达到的最低 LDLc 和患者未能达到临床目标 LDLc（
Background Apolipoprotein E (APOE) genotypes have been associated with variations in plasma-lipid levels and with response to statins, although the influence of APOE on the response to statins remains controversial, especially in patients with diabetes. We sought to evaluate the association of the APOE genotype with the low-density lipoprotein cholesterol (LDLc)-lowering response to statins, in a large population-based cohort of patients with diabetes.Methods and results A total of 1383 patients, commencing statins between 1990 and 2006, were identified from the Genetics of Diabetes Audit and Research in Tayside Scotland database. Statin response was determined both by the minimum LDLc achieved, and by the failure of the patients to reach a clinical target LDLc (